B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Friday, setting a price target of $106, which is approximately 29.57% above the present share price of $81.81.
Mamtani expects Arrowhead Pharmaceuticals to post earnings per share (EPS) of -$0.26 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Arrowhead Pharmaceuticals, with an average price target of $82.
The analysts price targets range from a high of $106 to a low of $34.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $32.81 million and a net profit of -$28.23 million. The company's market cap is $8.71 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.0% and a 57.69% success rate.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.